IP Library Patent Application 11789698
Patent Application
App. No. 11/789,698

Method for lowering serum glucose

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/789,698
Abstract

A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

Claims (9)

1 - 20 . (canceled)

21 . A method for reducing serum glucose levels in a human diabetic patient, comprising administering to said patient a therapeutically effective amount of a powder comprising colesevelam or a pharmaceutically acceptable salt thereof.

22 . The method of claim 21 , wherein the powder comprises a pharmaceutically acceptable salt of colesevelam.

23 . The method of claim 21 , wherein the powder is administered to the patient by incorporating it into a drink.

24 . The method of claim 22 , wherein the powder is administered to the patient by incorporating it into a drink.

25 . A method for reducing serum glucose levels in a human diabetic patient, comprising administering to said patient a therapeutically effective amount of a powder comprising colesevelam or a pharmaceutically acceptable salt thereof, wherein said colesevelam or pharmaceutically acceptable salt thereof is the only active ingredient administered to the patient.

26 . The method of claim 25 , wherein the powder comprises a pharmaceutically acceptable salt of colesevelam.

27 . The method of claim 25 , wherein the powder is administered to the patient by incorporating it into a drink.

28 . The method of claim 26 , wherein the powder is administered to the patient by incorporating it into a drink.